Technology
Health
Biotechnology

Trillium Therapeutics

$0.3436
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0094 (-2.66%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell TRIL and other stocks, options, ETFs, and crypto commission-free!

About TRIL

Trillium Therapeutics Inc. Common Shares, also called Trillium Therapeutics, is a clinical stage immuno-oncology company, which engages in the development of therapies for the treatment of cancer. Read More Its pipeline is comprised of TTI-621, TTI-622, and TTI-2341(EGFR Inhibitor). The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.

CEO
Employees
60
Headquarters
Mississauga, Ontario
Founded
2004
Market Cap
9.23M
Price-Earnings Ratio
Dividend Yield
Average Volume
220.95K
High Today
$0.366
Low Today
$0.342
Open Price
$0.3512
Volume
97.92K
52 Week High
$6.75
52 Week Low
$0.3003

Collections

Technology
Health
Biotechnology
Therapy
Medical
Cancer Prevention
2014 IPO
Canada

TRIL Earnings

-$0.91
-$0.81
-$0.71
-$0.61
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 7, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.